StockNews.AI
DVAX
Benzinga
189 days

Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty

1. Goldman Sachs downgraded DVAX from Neutral to Sell. 2. Shingles vaccine competition could impact Z-1018's value. 3. HEPLISAV-B revenue growth remains strong despite FDA concerns. 4. Analysts predict $278 million in sales for 2024. 5. Recent price drop of 4.13% signals market concern.

4m saved
Insight
Article

FAQ

Why Bearish?

The downgrade and price target cut indicate reduced confidence in future earnings, similar to past downgrades affecting stock prices.

How important is it?

The article discusses key competitive dynamics and financial forecasts directly impacting DVAX's market perception and valuation.

Why Short Term?

Immediate effects from the downgrade and competition could influence DVAX’s stock in the coming months as investors reassess their positions.

Related Companies

DVAXGSK

Related News